Abstract
HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 753-760 |
| Number of pages | 8 |
| Journal | Kidney International |
| Volume | 93 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2018 |
Fingerprint
Keywords
- antiretroviral therapy
- APOL1
- CKD progression
- HIV
- immune complex kidney disease
- podocytopathy
- renal pathology
ASJC Scopus subject areas
- Nephrology
Cite this
Kidney disease in the setting of HIV infection : conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. / Conference Participants.
In: Kidney International, Vol. 93, No. 3, 01.03.2018, p. 753-760.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Kidney disease in the setting of HIV infection
T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
AU - Conference Participants
AU - Swanepoel, Charles R.
AU - Atta, Mohamed G.
AU - D'Agati, Vivette D.
AU - Estrella, Michelle M.
AU - Fogo, Agnes B.
AU - Naicker, Saraladevi
AU - Post, Frank A.
AU - Wearne, Nicola
AU - Winkler, Cheryl A.
AU - Cheung, Michael
AU - Wheeler, David C.
AU - Winkelmayer, Wolfgang C.
AU - Wyatt, Christina M.
AU - Abu-Alfa, Ali
AU - Adu, Dwomoa
AU - Agodoa, Lawrence Y.
AU - Alpers, Charles E.
AU - Arogundade, Fatiu A.
AU - Ashuntantang, Gloria
AU - Bagnis, Corinne I.
AU - Bhimma, Raj
AU - Brocheriou, Isabelle
AU - Cohen, Arthur H.
AU - Cohen, Karen
AU - Cook, H. Terence
AU - de Seigneux, Sophie
AU - Fabian, June
AU - Finkelstein, Fredric O.
AU - Haas, Mark
AU - Hamzah, Lisa
AU - Hendry, Bruce M.
AU - Imonje, Valentine
AU - Jennette, J. Charles
AU - Kimmel, Paul L.
AU - Klotman, Mary E.
AU - Klotman, Paul E.
AU - Larsen, Chris P.
AU - McCulloch, Mignon I.
AU - Mosiane, Pulane
AU - Nast, Cynthia C.
AU - Okpechi, Ikechi G.
AU - Ray, Patricio E.
AU - Rosenberg, Avi Z.
AU - Ross, Michael J.
AU - Ryom, Lene
AU - Truong, Luan
AU - Ulasi, Ifeoma
AU - Vogt, Liffert
AU - Zeier, Martin
PY - 2018/3/1
Y1 - 2018/3/1
N2 - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.
AB - HIV-positive individuals are at increased risk for kidney disease, including HIV-associated nephropathy, noncollapsing focal segmental glomerulosclerosis, immune-complex kidney disease, and comorbid kidney disease, as well as kidney injury resulting from prolonged exposure to antiretroviral therapy or from opportunistic infections. Clinical guidelines for kidney disease prevention and treatment in HIV-positive individuals are largely extrapolated from studies in the general population, and do not fully incorporate existing knowledge of the unique HIV-related pathways and genetic factors that contribute to the risk of kidney disease in this population. We convened an international panel of experts in nephrology, renal pathology, and infectious diseases to define the pathology of kidney disease in the setting of HIV infection; describe the role of genetics in the natural history, diagnosis, and treatment of kidney disease in HIV-positive individuals; characterize the renal risk-benefit of antiretroviral therapy for HIV treatment and prevention; and define best practices for the prevention and management of kidney disease in HIV-positive individuals.
KW - antiretroviral therapy
KW - APOL1
KW - CKD progression
KW - HIV
KW - immune complex kidney disease
KW - podocytopathy
KW - renal pathology
UR - http://www.scopus.com/inward/record.url?scp=85041607294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041607294&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2017.11.007
DO - 10.1016/j.kint.2017.11.007
M3 - Article
VL - 93
SP - 753
EP - 760
JO - Kidney International
JF - Kidney International
SN - 0085-2538
IS - 3
ER -